Analysts size the obesity market at roughly 27% annual growth

Analysts published new forecasts on September 8, 2026, projecting that the obesity therapeutics market will expand at a compound annual growth rate of about 27% from 2022 through 2036, driven by oral GLP-1 medicines and a growing pipeline of new drugs.^[1] Separately, data presented by IQVIA at the AMCP Annual meeting counted about 190 obesity-related products currently in development.^[2]

Across the seven largest drug markets—the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan—the obesity market was valued at roughly $16 billion in 2025.^[1] The United States accounted for about 60% of the 190 million prevalent obesity cases tracked across those markets and generated nearly $13 billion in obesity treatment sales that year.^[1] IQVIA's separate analysis put total obesity therapeutics sales at close to $42 billion in 2025, giving the category a 4.6% share of the overall pharmaceutical market and making it the fourth-largest therapeutic category, behind immunology, antidiabetic drugs, and oncology.^[2]

Tirzepatide and semaglutide products led the category's growth. Eli Lilly's Zepbound reached $22.9 billion in 2025 sales, up 188.7% from the prior year, while Novo Nordisk's Wegovy reached $18.6 billion, up 29.2%.^[2] IQVIA projects obesity therapies will add about $100 billion in cumulative sales growth by 2029.^[2] Oral formulations are expected to be a major driver of that growth: the FDA approved a 25 mg oral version of semaglutide under the Wegovy brand in December 2025, and within three weeks of its United Kingdom launch, roughly 300,000 patients were estimated to be using it.^[1] Eli Lilly's once-daily oral orforglipron, sold as Foundayo, was approved in April 2026 for adults with obesity or overweight who have at least one weight-related health condition.^[1]

Pricing varies widely. Injectable Wegovy carries a U.S. list price of about $1,349 a month, though insurance or cash-pay programs can lower what patients actually pay.^[1] Zepbound is available through a self-pay program at about $299 to $449 a month depending on dose.^[1] Oral Wegovy and Foundayo launched with self-pay prices starting around $149 a month, with many higher-dose regimens priced between $299 and $349 a month.^[1]

Why it matters for patients

A fast-growing pipeline and more oral options could mean more choices and, potentially, easier access for patients who prefer pills over injections. But growth in the market does not automatically mean lower costs or better insurance coverage. IQVIA's data show that many independent pharmacies are opting out of dispensing obesity GLP-1 drugs: about 41% did not stock them in the fourth quarter of 2025, largely because of reimbursement rates.^[2] That could affect where patients can actually fill a prescription.

Staying on these medicines also remains a challenge. Among about 2.5 million patients studied who started an obesity GLP-1 drug, roughly 66.5% remained in retail pharmacy channels a year later, while about 28% stopped treatment entirely within that first year—a discontinuation rate researchers linked to cost, side effects, or inconsistent insurance coverage.^[2] That pattern suggests that even as new drugs enter the market, cost and coverage, not just drug availability, will likely continue to shape whether patients can stick with treatment.

What happens next

The report covering this forecast spans data through 2036, with additional analysis on pipeline drugs including enicepatide from Roche and Carmot Therapeutics and RGT-075 from Regor Therapeutics, both still in clinical testing.^[1] IQVIA's presentation projected obesity therapies would contribute roughly $100 billion in additional sales by 2029, a milestone that will depend on continued FDA approvals, manufacturing capacity, and insurance coverage decisions still unfolding.^[2]